Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
J Urol. 2018 May 11;:
Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis.
Oncotarget. 2018 Apr 10;9(27):18797-18810
High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis.
Oncotarget. 2018 Mar 30;9(24):16731-16743
Pathol Oncol Res. 2018 Apr 06;:
Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
Can Urol Assoc J. 2018 Mar 19;:
Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance.
J Urol. 2017 Dec 12;:
Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis.
Can Urol Assoc J. 2018 Feb 23;:
Clin Cancer Res. 2017 May 01;23(9):2169-2176
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Urol Oncol. 2018 Feb 14;:
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.
Bladder Cancer. 2018 Jan 20;4(1):91-112
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto